前列腺癌
癌症研究
下调和上调
mTORC1型
生物
丝氨酸
雄激素受体
信号转导
癌症
细胞生物学
磷酸化
PI3K/AKT/mTOR通路
生物化学
基因
遗传学
作者
Miguel Reina‐Campos,Juan F. Linares,Angeles Durán,Thekla Cordes,Antoine L’Hermitte,Mehmet G. Badur,Munveer S. Bhangoo,Phataraporn Thorson,Alicia Richards,Tarmo Rooslid,Dolores C. Garcı́a-Olmo,Syongh Y. Nam-Cha,A.S. Salinas Sánchez,Kenneth Wha Eng,Himisha Beltran,David A. Scott,Christian M. Metallo,Jorge Moscat,Marı́a T. Diaz-Meco
出处
期刊:Cancer Cell
[Cell Press]
日期:2019-02-28
卷期号:35 (3): 385-400.e9
被引量:163
标识
DOI:10.1016/j.ccell.2019.01.018
摘要
Increasingly effective therapies targeting the androgen receptor have paradoxically promoted the incidence of neuroendocrine prostate cancer (NEPC), the most lethal subtype of castration-resistant prostate cancer (PCa), for which there is no effective therapy. Here we report that protein kinase C (PKC)λ/ι is downregulated in de novo and during therapy-induced NEPC, which results in the upregulation of serine biosynthesis through an mTORC1/ATF4-driven pathway. This metabolic reprogramming supports cell proliferation and increases intracellular S-adenosyl methionine (SAM) levels to feed epigenetic changes that favor the development of NEPC characteristics. Altogether, we have uncovered a metabolic vulnerability triggered by PKCλ/ι deficiency in NEPC, which offers potentially actionable targets to prevent therapy resistance in PCa.
科研通智能强力驱动
Strongly Powered by AbleSci AI